Nurix Says Enters H2 Of 2024 Well Positioned To Develop Lead Clinical Program, NX-5948, Into Pivotal Clinical Trials In Chronic Lymphocytic Leukemia In 2025
Cash, cash equivalents and marketable securities was $452.5 million as of May 31, 2024, compared to $254.3 million as of February 29, 2024.